TrialMalaria journal2013

Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.

Nekoye Otsyula et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.